Natus Medical Incorporated (NASDAQ:BABY) Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $41.01, for a total value of $205,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Natus Medical Incorporated (BABY) traded down $0.15 on Wednesday, hitting $40.85. The stock had a trading volume of 500,700 shares, compared to its average volume of 386,740. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. The firm has a market cap of $1,277.32, a PE ratio of 26.45 and a beta of 0.89. Natus Medical Incorporated has a 1-year low of $31.65 and a 1-year high of $43.85.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million during the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The company’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the firm earned $0.39 EPS. sell-side analysts expect that Natus Medical Incorporated will post 1.74 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/15/natus-medical-incorporated-baby-director-william-m-moore-sells-5000-shares.html.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Tuesday, October 24th. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $46.50.

Institutional investors and hedge funds have recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Natus Medical by 2,085.6% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 2,607 shares during the period. Riverhead Capital Management LLC lifted its holdings in shares of Natus Medical by 90.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after buying an additional 1,364 shares during the period. Sei Investments Co. lifted its holdings in shares of Natus Medical by 29.7% in the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after buying an additional 728 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Natus Medical in the 3rd quarter valued at approximately $138,000. Finally, Victory Capital Management Inc. raised its holdings in Natus Medical by 17.6% during the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after purchasing an additional 560 shares during the last quarter. 99.53% of the stock is owned by institutional investors and hedge funds.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.